Cue BiopharmaCUE -3.38%59 Market Cap is $109.25 Mil as of Jun. 25, 2026. GuruFocus rates CUE with a GF Score™ of 59/100 and a GF Value™ of $62.11 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,431 Biotechnology companies, Cue Biopharma ranks worse than 51.01% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Cue Biopharma's share price for the quarter that ended in Mar. 2026 was $6.897. Cue Biopharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 3.26 Mil. Therefore, Cue Biopharma's market cap for the quarter that ended in Mar. 2026 was $22.45 Mil.
Cue Biopharma's quarterly market cap
declined
from Sep. 2025 ($55.91 Mil) to Dec. 2025 ($29.51 Mil) and
declined
from Dec. 2025 ($29.51 Mil) to Mar. 2026 ($22.45 Mil).
Cue Biopharma's annual market cap
declined
from Dec. 2023 ($124.66 Mil) to Dec. 2024 ($67.39 Mil) and
declined
from Dec. 2024 ($67.39 Mil) to Dec. 2025 ($29.51 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Cue Biopharma's Enterprise Value for Today is $96.31 Mil.
Cue Biopharma (NAS:CUE) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Cue Biopharma Market Cap Related Terms
Cue Biopharma Market Cap Historical Data
* Premium members only.
The historical data trend for Cue Biopharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cue Biopharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cue Biopharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cue Biopharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Cue Biopharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Cue Biopharma's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cue Biopharma (CUE) has a Market Cap of $109.25 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cue Biopharma and its competitors. According to the industry distribution chart, Cue Biopharma ranks #730 out of 1431 companies in the Biotechnology industry, placing it in the top 51%.
Is Cue Biopharma's Market Cap too high?
Cue Biopharma's current Market Cap is $109.25 Mil. The Biotechnology industry median Market Cap is 117.63. Cue Biopharma's value of $109.25 Mil is 7.1% below this industry median. Based on the distribution chart, Cue Biopharma ranks #730 out of 1431 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cue Biopharma has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's Market Cap compare to TELO and ACET?
According to the Biotechnology industry distribution chart, Cue Biopharma ranks #730 out of 1431 companies for Market Cap. This places Cue Biopharma in the lower half of its industry. The industry median Market Cap is 117.63. Cue Biopharma's value of $109.25 Mil is 7.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cue Biopharma's current Market Cap of $109.25 Mil is 7.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Cue Biopharma and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cue Biopharma's current Market Cap is $109.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cue Biopharma (CUE) is currently considered Possible Value Trap. The stock's GF Value™ is $62.11, compared to a current price of $26.01 — trading 58.1% below its estimated fair value. The current Market Cap is $109.25 Mil and 7.1% below the Biotechnology industry median of 117.63. Cue Biopharma's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Cue Biopharma (CUE), the current Market Cap is $109.25 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cue Biopharma (CUE) Overvalued in 2026?
Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued.
The current stock price of $26.01 is trading 58.1% below its estimated GF Value™ of $62.11.
GuruFocus considers Cue Biopharma to be Possible Value Trap.
Key valuation signals for CUE:
Market Cap: $109.25 Mil
GF Value™: $62.11 vs. price of $26.01 (58.1% below fair value)
Industry Position: 7.1% below the Biotechnology median (#730 of 1431)
No single metric tells the full story. See the CUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
59GF Score
Get the complete analysis for CUE
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUE has been successfully added to your 
